Insulin-lowering therapeutic modalities for polycystic ovary syndrome

Endocrinology and Metabolism Clinics of North America

Volumn 28, Issue 2, 1999, Pages 423-438

  Ehrmann, D A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; LEUPRORELIN; METFORMIN; TROGLITAZONE;

DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HORMONAL REGULATION; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0033017351     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70078-5     Document Type: Article

References (56)

1. O. Acbay S. Gundogdu Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 65 1996 946 949
2. C. Achard J. Thiers Le virilisme pilaire et son association a l'insuffisance glycolytique (diabete des femmes à barbe) Bull Acad Natl Med (Paris) 86 1921 51 64
3. G. Burghen J. Givens A. Kitabchi Correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease J Clin Endocrinol Metab 50 1980 113 116
4. J.B. Buse B. Gumbiner N.P. Mathias Troglitazone use in insulin-treated type 2 diabetic patients: The Troglitazone Insulin Study Group [in process citation] Diabetes Care 21 1998 1455 1461
5. F. Casimirri M. Biscotti A. Gambineri Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome Int J Obesity 21 suppl 2 1997 S61
6. R. Change R. Nakamura H. Judd Insulin resistance in nonobese patients with polycystic ovary syndrome J Clin Endocrinol Metab 57 1983 356 359
7. Crave J.-C. S. Fimbel H. Lejeune Effects of diet and metformin administration on sex hormone–binding globulin, androgens, and insulin in hirsute and obese women J Clin Endocrinol Metab 80 1995 2057 2062
8. E. Dahlgren P. Janson Johansson Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones Fertil Steril 57 1992 505 513
9. R. DeFronzo N. Barzilai D. Simonson Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects J Clin Endocrinol Metab 73 1991 1294 1301
10. E. Diamanti-Kandarakis C. Kouli T. Tsianateli Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome Eur J Endocrinol 138 1988 269 274
11. A. Duleba L. Pawelczyk Ho Yuen B. Insulin actions on ovarian steroidogenesis are not modulated by metformin Hum Reprod 8 1993 1194 1198
12. A. Dunaif D. Finegood β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome J Clin Endocrinol Metab 81 1996 942 947
13. A. Dunaif M. Graf J. Mandeli Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia J Clin Endocrinol Metab 65 1987 499 507
14. A. Dunaif A. Hoffman R. Scully The clinical, biochemical and ovarian morphologic features in women with acanthosis nigricans and masculinization Obstet Gynecol 66 1985 545 552
15. A. Dunaif D. Scott D. Finegood The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome J Clin Endocrinol Metab 81 1996 3299 3306
16. A. Dunaif K. Segal W. Futterweit Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome Diabetes 38 1989 1165 1174
17. A. Dunaif K. Segal D. Shelley Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome Diabetes 41 1992 1257 1266
18. A. Dunaif J. Xia C. Book Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: A potential mechanism for insulin resistance in the polycystic ovary syndrome J Clin Invest 96 1995 801 810
19. A. Dunaif Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis Endocr Rev 18 1997 774 800
20. D. Ehrmann R. Barnes R. Rosenfield Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism Endocr Rev 16 1995 322 353
21. D. Ehrmann M. Cavaghan J. Imperial Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome J Clin Endocrinol Metab 82 1997 524 530
22. Ehrmann D, Cavaghan M, Rosenfield R, et al: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, in press
23. Ehrmann D, Rosenfield R, Barnes R, et al: A longitudinal study of glucose tolerance in women with polycystic ovary syndrome. In Proceedings of the International Congress of Endocrinology, San Francisco, 1996
24. D. Ehrmann J. Sturis M. Byrne Insulin secretory defects in polycystic ovary syndrome: Relationship to insulin sensitivity and family history of non–insulin dependent diabetes mellitus J Clin Invest 96 1995 520 527
25. D.A. Ehrmann D.J. Schneider B.E. Sobel Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome J Clin Endocrinol Metab 82 1997 2108 2116
26. D.A. Ehrmann Relation of functional ovarian hyperandrogenism to non–insulin dependent diabetes mellitus Baillieres Clin Obstet Gynaecol 11 1997 335 347
27. I. Fantus R. Brosseau Mechanism of action of metformin: Insulin receptor and postreceptor effects in vitro and in vivo J Clin Endocrinol Metab 63 1986 898 905
28. S. Fendri X. Debussche H. Puy Metformin effects on peripheral sensitivity to insulin in nondiabetic obese subjects Diabete Metab 19 1993 245 249
29. V.A. Fonseca T.R. Valiquett S.M. Huang Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study. The Troglitazone Study Group J Clin Endocrinol Metab 83 1998 3169 3176
30. I. Hasegawa H. Murakawa M. Suzuki Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome Fertil Steril 71 2 1999 323 327
31. J. Holte T. Bergh C. Berne Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance J Clin Endocrinol Metab 78 1994 1052 1058
32. S.E. Inzucchi D.G. Maggs G.R. Spollett Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus [see comments] N Engl J Med 338 1998 867 872
33. R. Jackson M. Hawa J. Jaspan Mechanism of metformin action in non–insulin-dependent diabetes Diabetes 36 1987 632 640
34. S. Kahn R. Prigeon D. McCulloch Quantification of the relationship between insulin sensitivity and B-cell function in human subjects: Evidence for a hyperbolic function Diabetes 42 1993 1663 1672
35. D. Kiddy D. Hamilton-Fairley A. Bush Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome Clin Endocrinol 36 1992 105 111
36. Y. Kruszynska J. Olefsky Cellular and molecular mechanisms of non–insulin dependent diabetes mellitus J Invest Med 44 1996 413 428
37. Legro R, Dodson W, Dunaif A: PCOS: A reservoir of reproductive age glucose intolerance poorly detected by fasting blood glucose levels. Presented at the 80th Annual Meeting of The Endocrine Society, New Orleans, 1998
38. L. Morin-Papunen R. Koivunen A. Ruokonen Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome Fertil Steril 69 1998 691 696
39. J. Nestler C. Barlascini D.W. Matt Suppression of serum insulin levels by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome J Clin Endocrinol Metab 68 1989 1027 1032
40. J. Nestler D. Jakubowicz Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome N Engl J Med 335 1996 617 623
41. J.E. Nestler D.J. Jakubowicz W.S. Evans Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome N Engl J Med 338 1998 1876 1880
42. J.E. Nestler D.J. Jakubowicz Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens J Clin Endocrinol Metab 82 1997 4075 4079
43. N. O'Meara J. Blackman D.A. Ehrmann Defects in beta cell function and insulin action in functional ovarian hyperandrogenism J Clin Endocrinol Metab 76 1993 1241 1247
44. R. Pasquali F. Casimirri V. Vicennati Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome Hum Reprod 1 suppl 1997 82 87
45. E. Peters C. Stuart M. Prince Acanthosis nigricans and obesity: Acquired and intrinsic defects in insulin action Metabolism 35 1986 807 813
46. K. Polonsky B. Given L. Hirsch Abnormal patterns of insulin secretion in non–insulin dependent diabetes N Engl J Med 318 1988 1231 1239
47. K. Polonsky J. Sturis G. Bell Non–insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance N Engl J Med 334 1996 777 783
48. R. Rosenfield R. Barnes J. Cara Dysregulation of cytochrome P450c17a as the cause of polycystic ovary syndrome Fertil Steril 53 1990 785 791
49. A. Saltiel J. Olefsky Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 45 1996 1661 1669
50. C. Stuart E. Peters M. Prince Insulin resistance with acanthosis nigricans: The roles of obesity and androgen excess Metabolism 35 1986 197 205
51. Van der Spuy Z. R. Dhansay F. Nugent Adjuvant therapy with metformin to improve the therapeutic outcome in anovulatory hyperinsulinaemic women with polycystic ovary syndrome Hum Reprod 11 1996 167
52. E. Velazquez A. Acosta S. Mendoza Menstrual cyclicity after metformin therapy in polycystic ovary syndrome Obstet Gynecol 90 1997 392 395
53. E. Velazquez S. Mendoza T. Hamer Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and sytolic blood pressure, while facilitating normal menses and pregnancy Metabolism 43 1994 647 654
54. E. Velazquez S. Mendoza P. Wang Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome Metabolism 46 1997 454 457
55. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. (Technical Report Series No. 727). Geneva, World Health Organization, 1985
56. Wu M.-S. P. Johnston Sheu W.-H. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients Diabetes Care 13 1990 1 8